Neoleukin Therapeutics, Inc. (NLTX)
| Market Cap | 440.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.59M |
| Shares Out | 42.35M |
| EPS (ttm) | -2.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $10.40 |
| Previous Close | $10.63 |
| Change ($) | -0.23 |
| Change (%) | -2.16% |
| Day's Open | 10.66 |
| Day's Range | 10.39 - 10.80 |
| Day's Volume | 232,229 |
| 52-Week Range | 9.38 - 18.13 |
SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -
The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-...
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal se...
New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...
The company is experiencing regulatory headwinds.
Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-...
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -
- NL-201 IND submission anticipated by year end 2020 -
- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –
SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call Transcript
SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...
SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...
SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The development-stage drug company announced the pricing of a public offering of common stock.
SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...
SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo p...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.
SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein ...
Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript
SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...
Here are three stocks that have broken out of above resistance and are looking higher: Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protei...
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
About NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2003 |
| Stock Exchange NASDAQ | Ticker Symbol NLTX |
Analyst Forecasts
According to 8 analysts, the average rating for NLTX stock is "Strong Buy." The 12-month stock price forecast is 20.40, which is an increase of 96.15% from the latest price.